Genfit highlights Ipsen partnership economics, cash runway beyond 2028 in corporate presentation

• Genfit outlined its rare liver-disease focus, highlighting Ipsen-partnered Iqirvo launched for PBC with up to 20% tiered royalties.
• Cash position EUR 136.1 million in 1Q26; cash runway beyond 2028; no debt overhang.
• Iqirvo economics include EUR 120 million upfront; 8% equity stake; up to EUR 360 million milestones with EUR 105.5 million received.
• PSC program advanced with a Phase 3 trial launched for elafibranor; royalty financing with HCRx delivered EUR 160 million.
• Wholly owned growth drivers include MASH diagnostics NIS4/NIS2+ with Medicare reimbursement for Labcorp’s NASHnext effective Aug. 10, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.